CN114344490A - Radioactive metal particle for tumor contrast labeling - Google Patents
Radioactive metal particle for tumor contrast labeling Download PDFInfo
- Publication number
- CN114344490A CN114344490A CN202210039035.0A CN202210039035A CN114344490A CN 114344490 A CN114344490 A CN 114344490A CN 202210039035 A CN202210039035 A CN 202210039035A CN 114344490 A CN114344490 A CN 114344490A
- Authority
- CN
- China
- Prior art keywords
- radioactive
- outer layer
- metal particle
- radioactive metal
- tumor contrast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention belongs to the technical field of metal markers, and discloses a radioactive metal particle for tumor contrast labeling, wherein the metal marker is used for improving the internal and external structures on the basis of iodine-125 particles, and the improved radioactive metal particle comprises an inner layer and an outer layer, wherein the inner layer is coated by the outer layer; the inner layer is a mixture of a contrast agent and a radioactive isotope, the contrast agent comprises a solution and a filler, the solution is a transition metal complex solution, the filler adopts at least one of bone cement or lead, and the radioactive isotope adopts at least one of radioactive iodine-125, radioactive palladium-103 or radioactive cesium-131; the outer layer is made of medical degradable alloy, and the average wall thickness of the outer layer is 0.03-0.05 mm; in conclusion, the improvement of the internal structure of the particles is realized by adding bone cement, wherein the bone cement has the advantage of high safety, and the density of the bone cement is higher than that of iodine-125, so that the whole particles are easier to be imaged.
Description
Technical Field
The invention belongs to the technical field of metal markers, and particularly relates to a radioactive metal particle for tumor contrast labeling.
Background
As early as 20 years ago, researchers began to use radioactive metal particles for tumor labeling after biopsy, and then the literature reported the study of placing radioactive metal particles in ultrasound, X-ray, MRI-guided localization biopsy, and their clinical application was increasing.
At present, in many medical centers in China and even all over the world, radioactive metal particles of different types and categories are widely used in the treatment of various malignant Z tumors, such as axillary lymph node location after new adjuvant chemotherapy before breast cancer operation and metal marker location in radiotherapy of malignant tumor of radiotherapy radiowave knife. However, in some cases, the metal marker has no definite clinical indication, the clinical indications of various centers are greatly different, and no such products exist in China.
At present, radioactive metal particles for tumor marking are all replaced by cold chain iodine-125 particles, but the long-term clinical application shows that the cold chain iodine-125 particles have the following defects:
first, cold chain iodine-125 particles are not absolutely radioactive metal species, and are of a certain or very low radioactivity.
Secondly, the two ends of the cold chain iodine-125 particles are blunt and round, the surface is smooth, and the particles are easy to displace when being implanted into malignant tumor bodies.
Disclosure of Invention
In view of the above, it is an object of the present invention to provide a radioactive metal particle for tumor contrast labeling that solves the problems of the background art described above.
In order to achieve the purpose, the invention provides the following technical scheme: a radioactive metal particle for tumor contrast labeling, the metal marker is based on iodine-125 particles and is improved in internal and external structure, and the improved radioactive metal particle comprises an inner layer and an outer layer, wherein the inner layer is coated by the outer layer;
the inner layer is a mixture of a contrast agent and a radioactive isotope, the contrast agent comprises a solution and a filler, the solution is a transition metal complex solution, the filler adopts at least one of bone cement or lead, and the radioactive isotope adopts at least one of radioactive iodine-125, radioactive palladium-103 or radioactive cesium-131;
the outer layer is made of medical degradable alloy, and the average wall thickness of the outer layer is 0.03-0.05 mm.
Preferably, the outer layer includes a middle portion and end portions connected to both ends of the middle portion.
Preferably, the length of the middle part accounts for 2/3 of the total length of the outer layer, and the total length of the outer layer is 4-5 mm.
Preferably, the end surface is an arc surface, the cross-sectional shape of the middle portion is annular, and the outer diameter of the annular shape is not more than 0.8 mm.
Preferably, the middle part and the end parts at the two ends are formed by laser welding, and the junction of the middle part and the end parts is in smooth transition.
Preferably, the end portion is provided with an inner concave portion extending toward the middle portion; the inner recess occupies 1/2-7/8 of the end portion, and the inner recess comprises at least one inner groove. Furthermore, the cross section of the inner groove is arc-shaped, polygonal or conical, and the inner part of the inner groove and the connecting part between the edge of the inner groove and the end surface are in arc transition.
Preferably, the surface of the middle part is provided with threads extending towards two ends, and the threads at least comprise external threads.
Compared with the prior art, the invention has the following beneficial effects:
(1) in the invention, the external structure of the particle marker is improved, specifically, invaginations are arranged at two ends of the particle marker, and threads are arranged on the middle surface of the particle marker, so that the problem of displacement after the particle marker is implanted is effectively avoided.
(2) In the present invention, it is preferable to achieve the improvement of the internal structure of the particles by adding bone cement or lead, wherein the bone cement has the advantage of high safety and the density of the bone cement is higher than that of iodine-125, thereby making the whole particles more easily visualized.
In conclusion, the metal marker disclosed by the invention is used for positioning and marking the tumor, so that the precise positioning and tracking of the malignant tumor target focus under the guidance of an image can be realized, and the accuracy of subsequent operations and radiotherapy can be improved; in addition, the system is also beneficial to the auxiliary treatment of the evaluation of the curative effect and the surgical positioning of the primary focus and/or the lymph node focus of the patient, thereby ensuring the accuracy of pathological examination.
Drawings
FIG. 1 is an external view of a first embodiment of the present invention;
FIG. 2 is an external view of a second embodiment of the present invention;
FIG. 3 is a view showing an internal structure of a third embodiment of the present invention;
FIG. 4 is a view showing an internal structure of a fourth embodiment of the present invention;
FIG. 5 is an internal structural view of a fifth embodiment of the present invention;
in the figure: an inner layer-1; an outer layer-2; a middle portion-3; end-4; an inner recess-5; thread-6.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the invention, a radioactive metal particle for tumor contrast labeling is provided, specifically, an inner layer 1 and an outer layer 2 of the radioactive metal particle are provided, and the inner layer 1 is coated by the outer layer 2. Wherein:
the inner layer 1 is a mixture of a contrast agent and a radioactive isotope, the contrast agent comprises a solution and a filler, the solution is a transition metal complex solution, the filler is at least one of bone cement or lead, and the radioactive isotope is at least one of radioactive iodine-125, radioactive palladium-103 or radioactive cesium-131;
the outer layer 2 is made of medical degradable alloy, and the average wall thickness of the outer layer 2 is 0.03-0.05 mm.
The filler is preferably bone cement; in particular, bone cement has been used clinically for many years, has the advantage of high safety, and the density of bone cement is greater than that of iodine-125, so that the whole metal marker is easier to image.
In addition, the following embodiment structure is provided for the outer layer 2
Example one
A radioactive metal particle for tumor contrast labeling comprises an inner layer 1 and an outer layer 2, wherein the inner layer 1 is coated with the outer layer 2.
The outer layer 2 comprises a middle part 3 and end parts 4 connected to two ends of the middle part 3;
the intermediate portion 3 has threads 6 extending from both ends thereof.
The following steps:
the outer layer 2 is made of medical degradable titanium-based material with the thickness of 0.05 mm;
the length of the middle part 3 accounts for 2/3 of the total length of the outer layer 2, and the total length of the outer layer 2 is 4-5 mm (preferably 4.5 mm);
the surface of the end part 4 is a cambered surface, the cross section of the middle part 3 is annular, and the outer diameter of the annular is not more than 0.8 mm.
Specifically, in this embodiment, it can be seen from fig. 1 that:
the middle part 3 and the end parts 4 at two ends are formed by laser welding, and the connecting part of the middle part 3 and the end parts 4 is in smooth transition;
the threads 6 are arranged as equidistant external threads.
Example two
A radioactive metal particle for tumor contrast labeling comprises an inner layer 1 and an outer layer 2, wherein the inner layer 1 is coated with the outer layer 2.
The outer layer 2 comprises a middle part 3 and end parts 4 connected to two ends of the middle part 3;
the intermediate portion 3 has threads 6 extending from both ends thereof.
The following steps:
the outer layer 2 is made of medical degradable titanium-based material with the thickness of 0.05 mm;
the length of the middle part 3 accounts for 2/3 of the total length of the outer layer 2, and the total length of the outer layer 2 is 4-5 mm (preferably 4.5 mm);
the surface of the end part 4 is a cambered surface, the cross section of the middle part 3 is annular, and the outer diameter of the annular is not more than 0.8 mm.
Specifically, in this embodiment, it can be seen from fig. 2 that:
the middle part 3 and the end parts 4 at two ends are formed by laser welding, and the connecting part of the middle part 3 and the end parts 4 is in smooth transition;
the thread 6 is set to 1: 1, and the external thread and the internal thread are distributed at equal intervals.
EXAMPLE III
A radioactive metal particle for tumor contrast labeling comprises an inner layer 1 and an outer layer 2, wherein the inner layer 1 is coated with the outer layer 2.
The outer layer 2 comprises a middle part 3 and end parts 4 connected to two ends of the middle part 3;
the end portion 4 is provided with an inward recessed portion 5 extending toward the intermediate portion 3.
The following steps:
the outer layer 2 is made of medical degradable titanium-based material with the thickness of 0.05 mm;
the length of the middle part 3 accounts for 2/3 of the total length of the outer layer 2, and the total length of the outer layer 2 is 4-5 mm (preferably 4.5 mm);
the surface of the end part 4 is a cambered surface, the cross section of the middle part 3 is annular, and the outer diameter of the annular is not more than 0.8 mm.
Specifically, in this embodiment, it can be seen from fig. 3 that:
the middle part 3 and the end parts 4 at two ends are formed by laser welding, and the connecting part of the middle part 3 and the end parts 4 is in smooth transition;
the fillet 5 occupies 1/2-7/8 (preferably 5/8) of the end 4, and the fillet 5 comprises at least one fillet (only one fillet is shown for ease of illustration), the fillet in this particular embodiment being arcuate in cross-section.
In addition, as can be seen, the junction between the edge of the arc-shaped inner groove and the surface of the end portion 4 is in arc transition.
Example four
A radioactive metal particle for tumor contrast labeling comprises an inner layer 1 and an outer layer 2, wherein the inner layer 1 is coated with the outer layer 2.
The outer layer 2 comprises a middle part 3 and end parts 4 connected to two ends of the middle part 3;
the end portion 4 is provided with an inward recessed portion 5 extending toward the intermediate portion 3.
The following steps:
the outer layer 2 is made of medical degradable titanium-based material with the thickness of 0.05 mm;
the length of the middle part 3 accounts for 2/3 of the total length of the outer layer 2, and the total length of the outer layer 2 is 4-5 mm (preferably 4.5 mm);
the surface of the end part 4 is a cambered surface, the cross section of the middle part 3 is annular, and the outer diameter of the annular is not more than 0.8 mm.
Specifically, in this embodiment, it can be seen from fig. 4 that:
the middle part 3 and the end parts 4 at two ends are formed by laser welding, and the connecting part of the middle part 3 and the end parts 4 is in smooth transition;
the inner recess 5 occupies 1/2-7/8 (preferably 5/8) of the end portion 4, and the inner recess 5 includes at least one inner groove (only one inner groove is shown for convenience of illustration), and the cross-sectional shape of the inner groove in the specific embodiment is a polygon (shown as a U-shape in the figure).
In addition, as can be seen, the junction between the edge of the arc-shaped inner groove and the surface of the end portion 4 is in arc transition.
EXAMPLE five
A radioactive metal particle for tumor contrast labeling comprises an inner layer 1 and an outer layer 2, wherein the inner layer 1 is coated with the outer layer 2.
The outer layer 2 comprises a middle part 3 and end parts 4 connected to two ends of the middle part 3;
the end portion 4 is provided with an inward recessed portion 5 extending toward the intermediate portion 3.
The following steps:
the outer layer 2 is made of medical degradable titanium-based material with the thickness of 0.05 mm;
the length of the middle part 3 accounts for 2/3 of the total length of the outer layer 2, and the total length of the outer layer 2 is 4-5 mm (preferably 4.5 mm);
the surface of the end part 4 is a cambered surface, the cross section of the middle part 3 is annular, and the outer diameter of the annular is not more than 0.8 mm.
Specifically, in this embodiment, it can be seen from fig. 5 that:
the middle part 3 and the end parts 4 at two ends are formed by laser welding, and the connecting part of the middle part 3 and the end parts 4 is in smooth transition;
the fillet 5 occupies 1/2-7/8 (preferably 5/8) of the end portion 4, and the fillet 5 comprises at least one fillet (only one fillet is shown for convenience of illustration), and the fillet in the embodiment is tapered in cross-section (shown as a V-shape).
In addition, as can be seen, the junction between the edge of the arc-shaped inner groove and the surface of the end portion 4 is in arc transition.
In conclusion, the invention improves the internal and external structures based on the iodine-125 particles, particularly improves the internal structure by sinking two ends and indicating threads, and improves the internal structure by adding bone cement; in addition, the outer layer 2 is preferably made of medical degradable alloy, so that the whole radioactive metal particles are made of safe materials harmless to human bodies, thereby effectively avoiding the operation complications such as secondary infection, allergy and the like caused by the radioactive metal particles in the using process, and further greatly improving the using safety of the radioactive metal particles.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (10)
1. A radioactive metal particle for tumor contrast labeling, comprising an inner layer (1) and an outer layer (2), wherein the inner layer (1) is coated with the outer layer (2);
the inner layer (1) is a mixture of a contrast agent and a radioactive isotope, the contrast agent comprises a solution and a filler, the solution is a transition metal complex solution, the filler adopts at least one of bone cement or lead, and the radioactive isotope adopts at least one of radioactive iodine-125, radioactive palladium-103 or radioactive cesium-131;
the outer layer (2) is made of medical degradable alloy, and the average wall thickness of the outer layer (2) is 0.03-0.05 mm.
2. The radioactive metal particle for tumor contrast labeling according to claim 1, wherein: the outer layer (2) comprises a middle part (3) and end parts (4) connected to two ends of the middle part (3).
3. The radioactive metal particle for tumor contrast labeling according to claim 2, wherein: the length of the middle part (3) accounts for 2/3 of the total length of the outer layer (2), and the total length of the outer layer (2) is 4-5 mm.
4. The radioactive metal particle for tumor contrast labeling according to claim 2, wherein: the surface of the end part (4) is an arc surface, the cross section of the middle part (3) is annular, and the outer diameter of the annular is not more than 0.8 mm.
5. The radioactive metal particle for tumor contrast labeling according to claim 2, wherein: the middle part (3) and the end parts (4) at the two ends are formed by laser welding, and the connecting part of the middle part (3) and the end parts (4) is in smooth transition.
6. The radioactive metal particle for tumor contrast labeling according to claim 2, wherein: the end portion (4) is provided with an inner concave portion (5) extending toward the intermediate portion (3).
7. The radioactive metal particle for tumor contrast labeling according to claim 6, wherein: the inner recess (5) occupies 1/2-7/8 of the end portion (4), and the inner recess (5) comprises at least one inner groove.
8. The radioactive metal particle for tumor contrast labeling according to claim 7, wherein: the cross section of the inner groove is arc-shaped, polygonal or conical, and the inner part of the inner groove and the joint between the edge of the inner groove and the surface of the end part (4) are in arc transition.
9. The radioactive metal particle for tumor contrast labeling according to claim 2, wherein: and the surface of the middle part (3) is provided with threads (6) extending towards two ends.
10. The radiometal particle for tumor contrast labeling according to claim 9, wherein: the thread (6) comprises at least an external thread.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210039035.0A CN114344490A (en) | 2022-01-13 | 2022-01-13 | Radioactive metal particle for tumor contrast labeling |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210039035.0A CN114344490A (en) | 2022-01-13 | 2022-01-13 | Radioactive metal particle for tumor contrast labeling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114344490A true CN114344490A (en) | 2022-04-15 |
Family
ID=81108696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210039035.0A Withdrawn CN114344490A (en) | 2022-01-13 | 2022-01-13 | Radioactive metal particle for tumor contrast labeling |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114344490A (en) |
-
2022
- 2022-01-13 CN CN202210039035.0A patent/CN114344490A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Havrilla et al. | Computed tomography and obstructive biliary disease | |
| JP5296276B2 (en) | Products and methods for brachytherapy | |
| Linda et al. | Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes | |
| Petrich et al. | Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age | |
| Brown et al. | Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment | |
| JP2003533301A (en) | Grochytherapy source with groove | |
| de Pont et al. | 124 I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131 I SPECT/CT | |
| CN114344490A (en) | Radioactive metal particle for tumor contrast labeling | |
| Romaldini | Case selection and restrictions recommended to patients with hyperthyroidism in South America | |
| CN104698063B (en) | A kind of method for determining Bone m etabolism exchange rate changing value | |
| CN113440742A (en) | Metal marker for tumor localization | |
| Zhang et al. | Treatment of portal vein tumor thrombus using 125Iodine seed implantation brachytherapy | |
| Hatabu et al. | Undifferentiated carcinoma of the thyroid gland: sonographic findings | |
| Donohue et al. | Stage I nonseminomatous germ-cell testicular cancer—management options and risk-benefit considerations | |
| McCullagh | Radioactive iodine in the treatment of hyperthyroidism | |
| GORDON et al. | Scanning of the Hepatic Blood Pool in the Differential Diagnosis of Space-Occupying Lesions of the Liver: With Emphasis on Amebic Abscess | |
| CN212282537U (en) | Radioactive particle loader | |
| Chai et al. | Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancer | |
| CN217938924U (en) | Radiotherapeutic markers | |
| CUARÓN et al. | Scanning of the hepatic blood pool in liver amebiasis | |
| Wolfstein | Enigma of the “hyperfunctioning” thyroid carcinoma resolved? | |
| CN219230156U (en) | Mammary tissue marker | |
| Song et al. | Diagnostic value of imaging modalities in primary squamous cell carcinoma of the liver | |
| CN210472814U (en) | Non-metal source applicator for after-loading radiotherapy | |
| Mafee et al. | Modern methodologies of differentiating thyroid masses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220415 |
|
| WW01 | Invention patent application withdrawn after publication |